Media headlines about Fate Therapeutics (NASDAQ:FATE) have trended somewhat positive on Thursday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fate Therapeutics earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.1332483357432 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Fate Therapeutics, Inc. (FATE) stock forward in overbought space? – Nasdaq Chronicle (nasdaqchronicle.com)
- Two Eye-Catching Stocks: Fate Therapeutics, Inc. (NASDAQ:FATE), Rent-A-Center, Inc. (NASDAQ:RCII) – The Oracle Examiner (oracleexaminer.com)
- High-Risky stock to Watch: Fate Therapeutics, Inc. (FATE) – Investor … – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Lookout for Relative Strength Index – Fate Therapeutics, Inc. (NASDAQ: FATE) – The Investor Guide (wallstreetnews24.com)
- Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors – GlobeNewswire (press release) (globenewswire.com)
Several research firms have recently weighed in on FATE. ValuEngine raised Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub raised Fate Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 23rd. Zacks Investment Research downgraded Fate Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 22nd. Wedbush reissued an “outperform” rating and issued a $7.00 price objective (down from $10.00) on shares of Fate Therapeutics in a report on Thursday, January 18th. Finally, Piper Jaffray Companies began coverage on Fate Therapeutics in a report on Monday, December 18th. They issued an “overweight” rating and a $10.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $7.71.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Fate Therapeutics (FATE) Share Price” was first published by BBNS and is the property of of BBNS. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://baseballnewssource.com/markets/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-fate-therapeutics-fate-share-price/1900221.html.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.